Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.

McDermott U, Settleman J.

J Clin Oncol. 2009 Nov 20;27(33):5650-9. doi: 10.1200/JCO.2009.22.9054. Epub 2009 Oct 26. Review.

PMID:
19858389
2.

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.

Workman P.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. Epub 2003 Jun 18. Review.

PMID:
12819933
3.

Somatic pharmacogenomics in cancer.

Ikediobi ON.

Pharmacogenomics J. 2008 Oct;8(5):305-14. doi: 10.1038/tpj.2008.8. Epub 2008 Aug 5. Review.

PMID:
18679398
4.

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

Faivre S, Djelloul S, Raymond E.

Semin Oncol. 2006 Aug;33(4):407-20. Review.

PMID:
16890796
5.

Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.

Patel JD, Pasche B, Argiris A.

Crit Rev Oncol Hematol. 2004 Jun;50(3):175-86. Review.

PMID:
15182824
6.

Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.

Vaidya AP, Parnes AD, Seiden MV.

Curr Treat Options Oncol. 2005 Mar;6(2):103-14. Review.

PMID:
15717992
7.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
8.

The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.

Hirsch FR.

Oncogene. 2009 Aug;28 Suppl 1:S1-3. doi: 10.1038/onc.2009.195.

PMID:
19680291
9.

Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors.

Perea S, Hidalgo M.

Clin Lung Cancer. 2004 Dec;6 Suppl 1:S30-4. Review.

PMID:
15638955
10.

Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology.

Lorusso PM, Eder JP.

Expert Opin Investig Drugs. 2008 Jul;17(7):1013-28. doi: 10.1517/13543784.17.7.1013 . Review.

PMID:
18549338
11.

Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.

Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, Curigliano G, Del Tacca M.

Pharmacol Rev. 2003 Mar;55(1):57-103. Review.

14.
15.

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

American Society of Clinical Oncology..

J Clin Oncol. 2003 Jun 15;21(12):2397-406. Epub 2003 Apr 11.

PMID:
12692171
16.

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.

Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML.

Cold Spring Harb Symp Quant Biol. 2005;70:73-81.

PMID:
16869740
17.

EGFR FISH versus mutation: different tests, different end-points.

Cappuzzo F.

Lung Cancer. 2008 May;60(2):160-5. doi: 10.1016/j.lungcan.2008.02.008. Epub 2008 Mar 25. Review.

PMID:
18367287
18.

New targets for non-small-cell lung cancer therapy.

Alvarez M, Roman E, Santos ES, Raez LE.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1423-37. Review.

PMID:
17944567
19.

Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).

Settleman J.

Semin Oncol. 2009 Apr;36(2 Suppl 1):S36-41. doi: 10.1053/j.seminoncol.2009.02.006.

PMID:
19393834
20.

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.

Bonomi PD, Buckingham L, Coon J.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4606-12. Review.

Supplemental Content

Support Center